Latest Us Market News

Starpharma has secured FDA alignment on the clinical development plan for its DEP® HER2 radiotherapy candidate, paving the way for a first-in-human phase 1 study in advanced HER2-positive cancers scheduled for H2 2026.

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

QuickFee reported a 9% normalised revenue decline in Q3 FY26, driven by US finance weakness post-US Pay Now sale, while Australian legal disbursement funding surged, underpinning confidence in FY26 earnings guidance.

OD6 Metals has secured a strategic foothold in the US critical minerals market by acquiring the Quinn Fluorspar Project in Nevada, delivering ultra-high-grade assay results and commencing systematic exploration. Meanwhile, metallurgical progress at its Splinter Rock rare earths project and new copper targets at Gulf Creek underpin a diversified critical minerals portfolio.

AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.

Janus Electric has unveiled a comprehensive growth strategy targeting over 1,600 electrified heavy trucks by FY29, leveraging its unique retrofit and battery swap technology across multiple international markets.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Zip Co reported a 41.5% jump in third quarter cash EBTDA to $65.1 million, driven by accelerated US transaction volume growth of 43.1% and steady credit losses. The company upgraded its FY26 cash EBTDA guidance to at least $260 million, highlighting robust profitability and expanding customer engagement.

Carbonxt Group has secured $750,000 through convertible notes from major shareholder Phelbe Pty Ltd, targeting expansion of its Minnesota pellet manufacturing and increasing its New Carbon Processing stake to 48.1%.

Iondrive Limited has confirmed over 90% extraction of key rare earth elements neodymium and praseodymium from US commercial samples, exceeding prior economic assumptions and advancing its modular recycling technology toward commercial deployment.